Zhejiang Starry Pharmaceutical (603520.SH) released a pre-loss announcement, expecting a net loss of 31 million to 25 million yuan in the fiscal year 2024.

Zhejiang Starry Pharmaceutical (603520.SH) released its annual performance forecast for 2024, predicting a net loss attributable to the owners of the parent company of 25 million to 31 million RMB for the full year of 2024, and a net loss of 33 million to 39 million RMB after deducting non-recurring gains and losses.